Literature DB >> 24201120

Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.

Umberto Gianelli1, Anna Bossi2, Ivan Cortinovis2, Elena Sabattini3, Claudio Tripodo4, Emanuela Boveri5, Alessia Moro6, Riccardo Valli7, Maurilio Ponzoni8, Ada M Florena4, Giulio F Orcioni9, Stefano Ascani10, Emanuela Bonoldi11, Alessandra Iurlo12, Luigi Gugliotta13, Vito Franco4.   

Abstract

This study, performed on behalf of the Italian Registry of Thrombocythaemias (Registro Italiano Trombocitemie), aimed to test the inter-observer reproducibility of the histological parameters proposed by the WHO classification for the diagnosis of the Philadelphia chromosome-negative myeloproliferative neoplasms. A series of 103 bone marrow biopsy samples of Philadelphia chromosome-negative myeloproliferative neoplasms consecutively collected in 2004 were classified according to the WHO criteria as follows: essential thrombocythaemia (n=34), primary myelofibrosis (n=44) and polycythaemia vera (n=25). Two independent groups of pathologists reviewed the bone marrow biopsies. The first group was asked to reach a collegial 'consensus' diagnosis. The second group reviewed individually all the cases to recognize the main morphological parameters indicated by the WHO classification and report their results in a database. They were subsequently instructed to individually build a 'personal' diagnosis of myeloproliferative neoplasms subtype just assembling the parameters collected in the database. Our results indicate that high levels of agreement (≥70%) have been reached for about all of the morphological features. Moreover, among the 18 evaluated histological features, 11 resulted statistically more useful for the differential diagnosis among the different Philadelphia chromosome-negative myeloproliferative neoplasms. Finally, we found a high percentage of agreement (76%) between the 'personal' and 'consensus' diagnosis (Cohen's kappa statistic >0.40). In conclusion, our results support the use of the histological criteria proposed by the WHO classification for the Philadelphia chromosome-negative myeloproliferative neoplasms to ensure a more precise and early diagnosis for these patients.

Entities:  

Mesh:

Year:  2013        PMID: 24201120     DOI: 10.1038/modpathol.2013.196

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

1.  The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.

Authors:  Umberto Gianelli; Daniele Cattaneo; Anna Bossi; Ivan Cortinovis; Leonardo Boiocchi; Yen-Chun Liu; Claudia Augello; Arturo Bonometti; Stefano Fiori; Nicola Orofino; Francesca Guidotti; Attilio Orazi; Alessandra Iurlo
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

2.  JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Waihay J Wong; Robert P Hasserjian; Geraldine S Pinkus; Lawrence J Breyfogle; Ann Mullally; Olga Pozdnyakova
Journal:  Haematologica       Date:  2017-11-16       Impact factor: 9.941

Review 3.  Advances and challenges in the management of essential thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Ther Adv Hematol       Date:  2015-06

4.  Efficient and Highly Accurate Diagnosis of Malignant Hematological Diseases Based on Whole-Slide Images Using Deep Learning.

Authors:  Chong Wang; Xiu-Li Wei; Chen-Xi Li; Yang-Zhen Wang; Yang Wu; Yan-Xiang Niu; Chen Zhang; Yi Yu
Journal:  Front Oncol       Date:  2022-06-10       Impact factor: 5.738

5.  Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.

Authors:  Serena Rupoli; Gaia Goteri; Paola Picardi; Giorgia Micucci; Lucia Canafoglia; Anna Rita Scortechini; Irene Federici; Federica Giantomassi; Lidia Da Lio; Antonio Zizzi; Elisa Honorati; Pietro Leoni
Journal:  Diagn Pathol       Date:  2015-04-16       Impact factor: 2.644

6.  Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Authors:  H Gisslinger; G Jeryczynski; B Gisslinger; A Wölfler; S Burgstaller; V Buxhofer-Ausch; M Schalling; M-T Krauth; A-I Schiefer; C Kornauth; I Simonitsch-Klupp; C Beham-Schmid; L Müllauer; J Thiele
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

7.  Quantification of IGF-1 Receptor May Be Useful in Diagnosing Polycythemia Vera-Suggestion to Be Added to Be One of the Minor Criterion.

Authors:  Jen C Wang; Guanfang Shi; Stacey Baptiste; Maryna Yarotska; Hemant Sindhu; Ching Wong; Madhumati Kalavar; Vladimir Gotlieb; Andrei Bandarchuk; Hui Chen
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

Review 8.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

9.  Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.

Authors:  I S Tiong; D A Casolari; T Nguyen; M J M Van Velzen; K Ambler; R J D'Andrea; D M Ross
Journal:  Blood Cancer J       Date:  2016-08-19       Impact factor: 11.037

10.  [Pathological characteristics of megakaryocytes in myeloproliferative neoplasms and their correlation with driver gene mutations].

Authors:  Z X Shi; P H Zhang; B Li; L H Fang; Z F Xu; T J Qin; J Q Liu; N B Hu; L J Pan; S Q Qu; D Liu; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.